Home Cart Sign in  
Chemical Structure| 2754-41-8 Chemical Structure| 2754-41-8

Structure of 2754-41-8

Chemical Structure| 2754-41-8

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Product Citations      Show More

Ingrid Marie Heyns ; Meenakshi Arora ; Raghu Ganugula ; Swetha Reddy Allamreddy ; Shrusti Tiwari ; Dhaval K Shah , et al.

Abstract: Receptor-mediated polyester drug delivery systems have tremendous potential for improving the clinical performance of existing pharmaceutical drugs. Despite significant progress made in this area, it remains unclear how and to what extent the polyester nanoparticle surface topography would affect the in vitro, ex vivo and in vivo performance of a drug, and if there exists a correlation between in vitro and in vivo, as well as healthy versus pathophysiological states. Herein, we report a systematic investigation of the interactions between ligands and receptors as a function of the linker length, two-carbon (2C) versus four-carbon (4C). The in vitro, ex vivo and in vivo in healthy models validate the hypothesis that 4C has better reach and binding to the receptors. The results indicate that 4C offered better performance over 2C in vivo in improving the oral bioavailability of insulin (INS) by 1.1-fold (3.5-fold compared to unfunctionalized nanoparticles) in a healthy rat model. Similar observations were made in pathophysiological models; however, the effects were less prominent compared to those in healthy models. Throughout, ligand decorated nanoparticles outperformed unfunctionalized nanoparticles. Finally, a semimechanistic pharmacokinetic and pharmacodynamic (PKPD) model was developed using the experimental data sets to quantitatively evaluate the effect of P2Ns-GA on oral bioavailability and efficacy of insulin. The study presents a sophisticated oral delivery system for INS or hydrophilic therapeutic cargo, highlighting the significant impact on bioavailability that minor adjustments to the surface can have.

Keywords: nanobiointerface ; nanotopography ; oral insulin delivery ; polyester nanoparticles ; receptor-mediated transcytosis

Purchased from AmBeed:

Raghu Ganugula ; Kabirat T. Babalola ; Ingrid M. Heyns ; Meenakshi Arora ; Sandeep.K. Agarwal ; Chandra Mohan , et al.

Abstract: One-third of systemic lupus erythematosus (SLE) patients experience various degrees of ocular manifestations, with immunosuppressants recommended as a treatment option. Targeted immune suppression via oral administration is challenging due to the harsh gastrointestinal tract environment combined with complex physiological barriers. Here, we report the efficacy of orally administered (CsA)-laden polymer nanoparticles decorated with the ligand – (P2Ns-GA-CsA) in sustained lymph node delivery. This is the first report demonstrating the CD71 specificity of P2Ns-GA-CsA in the CD71 knockout mouse model and the influence of spacer length in achieving target tissue bioavailability in a lupus mouse model. P2Ns-GA-CsA effectively regulates T-cell chemotaxis by PD-L1 at a 50 % lower dose compared to conventional CsA in a mouse model exhibiting lupus-associated corneal inflammation. Collectively, these results suggest the possibility for further development of P2Ns-GA to target a diverse range of lymphatic disorders

Keywords: Systemic Lupus Erythematosus ; Cornea ; Programmed Cell Death- Ligand 1 ; Lymph Node Targeting

Purchased from AmBeed:

W. Pula ; R. Ganugula ; E. Esposito ; M.N.V. Ravi Kumar ; M. Arora ;

Abstract: Functional polymer-lipid hybrid nanoparticles (H-NPs) are a promising class of nanocarriers that combine the benefits of polymer and lipid nanoparticles, offering biocompatibility, structural stability, high loading capacity, and, most importantly, superior surface functionalization. Here, we report the synthesis and design of highly functional H-NPs with specificity toward the transferrin receptor (TfR), using a small molecule ligand, gambogic acid (GA). A fluorescence study revealed the molecular orientation of H-NPs, where the lipid-dense core is surrounded by a polymer exterior, functionalized with GA. Urolithin A, an immunomodulator and anti-inflammatory agent, served as a model drug-like compound to prepare H-NPs via traditional emulsion-based techniques, where H-NPs led to smaller particles (132 nm) and superior entrapment efficiencies (70 % at 10 % drug loading) compared to GA-conjugated polymeric nanoparticles (P-NPs) (157 nm and 52 % entrapment efficiency) and solid lipid nanoparticles (L-NPs) (186 nm and 29 % entrapment efficiency). H-NPs showed superior intracellular accumulation compared to individual NPs using human small intestinal epithelial (FHs 74) cells. The in vitro efficacy was demonstrated by flow cytometry analysis, in which UA-laden H-NPs showed excellent anti-inflammatory properties in cisplatin-induced injury in healthy human proximal tubular cell (HK2) model by decreasing the TLR4, NF-κβ, and IL-β expression. This preliminary work highlights the potential of H-NPs as a novel functional polymer-lipid drug delivery system, establishing the foundation for future research on its therapeutic potential in addressing chemotherapy-induced acute kidney injury in cancer patients.

Keywords: Anti-inflammatory ; Polymer-lipid hybrid nanoparticles ; Tubular injury ; Urolithin A

Purchased from AmBeed:

Alternative Products

Product Details of [ 2754-41-8 ]

CAS No. :2754-41-8
Formula : C10H8O6
M.W : 224.17
SMILES Code : O=C1OC(C2CC3C(C(OC3=O)=O)CC12)=O
MDL No. :MFCD13704912
InChI Key :LJMPOXUWPWEILS-UHFFFAOYSA-N
Pubchem ID :14453667

Safety of [ 2754-41-8 ]

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338
 

Historical Records

Categories

Related Functional Groups of
[ 2754-41-8 ]

Anhydrides

Chemical Structure| 140651-06-5

A633171 [140651-06-5]

4-Ethylhexahydroisobenzofuran-1,3-dione

Similarity: 1.00

Chemical Structure| 676642-36-7

A623128 [676642-36-7]

1,3-Dioxooctahydroisobenzofuran-5,6-dicarboxylic acid

Similarity: 1.00

Chemical Structure| 25550-51-0

A125363 [25550-51-0]

Methylhexahydrophthalic anhydride(mix)

Similarity: 1.00

Chemical Structure| 19438-60-9

A369417 [19438-60-9]

5-Methylhexahydroisobenzofuran-1,3-dione

Similarity: 1.00

Chemical Structure| 13149-00-3

A304183 [13149-00-3]

cis-1,2-Cyclohexanedicarboxylic anhydride

Similarity: 1.00